Jubilant Life Sciences advances on receiving USFDA's approval for Draximage DTPA

29 Dec 2017 Evaluate

Jubilant Life Sciences is currently trading at Rs. 795.05, up by 24.50 points or 3.18% from its previous closing of Rs. 770.55 on the BSE.

The scrip opened at Rs. 778.95 and has touched a high and low of Rs. 799.75 and Rs. 778.00 respectively. So far 69,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 879.10 on 12-Apr-2017 and a 52 week low of Rs. 600.00 on 25-Oct-2017.

Last one week high and low of the scrip stood at Rs. 808.40 and Rs. 759.80 respectively. The current market cap of the company is Rs. 12,663.00 crore.

The promoters holding in the company stood at 54.02%, while Institutions and Non-Institutions held 24.66% and 21.32% respectively.

Jubilant Life Sciences’ material wholly owned subsidiary - Jubilant Pharma, through one of its wholly owned subsidiaries, has received a Supplemental New Drug Application (sNDA) approval from US Food and Drug Administration (USFDA) for Draximage DTPA powder for solution. Specifically, Draximage DTPA is a kit for the preparation of Technetium Tc99m pentetate injection.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.


Jubilant Pharmova Share Price

1130.85 -0.25 (-0.02%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.